Clinical trials evaluating potential therapies for light chain (AL) amyloidosis.

ABSTRACT:

Introduction

The field of systemic amyloidosis is experiencing major advances in diagnostic and prognostic methods coupled with a growing availability in treatment options.

Areas covered

Treatment of AL amyloidosis traditionally targeted the clonal plasma cells, in order to block further production of amyloidogenic light chains. Currently, a research focus is placed on targeting the already formed amyloid deposits using monoclonal antibodies against epitopes on such deposits. Encouraging results were obtained from the three investigated antibodies: NEOD001, 11-1F4 and anti-SAP, but further validation is required before these antibodies can be commercialized. In this paper, we review the current active clinical research in AL amyloidosis, which includes the monoclonal antibod

SUBMITTER: Muchtar E 

PROVIDER: S-EPMC8460071 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature